Advanced search
Start date
Betweenand

Multi-User Equipment approved in grant 18/14275-5: Nucleofector 4D - equipment used for genomic editing

Grant number: 19/09474-1
Support type:Multi-user Equipment Program
Duration: November 01, 2019 - October 31, 2026
Field of knowledge:Biological Sciences - Genetics - Human and Medical Genetics
Principal Investigator:Silvano Mario Attilio Raia
Grantee:Silvano Mario Attilio Raia
Home Institution: Instituto de Biociências (IB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated research grant:18/14275-5 - National production of genetically modified pigs for organ xenotransplantation in humans, AP.PITE
As informações de acesso ao Equipamento Multiusuário são de responsabilidade do Pesquisador responsável
EMU web page: Página do Equipamento Multiusuário não informada
Tipo de equipamento:Processos Biológicos - Crescimento e manipulação - Transfecção
Fabricante: Fabricante não informado
Modelo: Modelo não informado

Abstract

Motivated by the growing need for transplantation-available organs and the latest developments in genomic editing technologies such as the CRISPR-Cas9 system, significant progress in the efficiency and safety of xenotransplantation techniques has been achieved in the last two years. Genetically engineered pigs developed to prevent receptor hyperacute immune rejection have been successfully developed in other countries. However, the possibility of cross-infection of pathogens such as PERVs (porcine endogenous retrovirus) must be controlled before the starting of therapeutic trials in humans. This project proposes the innovative national production of genetically modified pigs where genes known as inducers of hyperacute rejection (GGTA1 / CMAH / ²4GalNT2) will be knocked out. Furthermore, the copies of the PERV pol gene will be inactivated from the porcine genomic DNA. To this end, this project associates geneticists, immunologists, surgeons and clinicians with known experience and credibility in their respective area of knowledge for the development of a national biotechnological based product. At the very end, we aim to provide the population in waiting list for transplants a viable alternative and definitive therapy, thus shortening the suffering of the patients and their families. Furthermore, besides technological aspects, the viability of xenotransplantation in Brazil will require great efforts to conciliate ethical, religious and legal aspects. On this respect, our previous experience as a pioneer of intervivos liver transplantation in the world in the 80s will be extremely valuable. This equipment will make possible the execution of the protocols related to this project and others. (AU)